Drug Profile
Research programme: musculoskeletal disorder therapeutics - Sanofi/Santhera
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Santhera Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Musculoskeletal disorders
Most Recent Events
- 12 Mar 2008 Discontinued - Preclinical for Musculoskeletal disorders in Switzerland (unspecified route)
- 12 Mar 2008 Discontinued - Preclinical for Musculoskeletal disorders in USA (unspecified route)
- 11 Oct 2004 Preclinical trials in Musculoskeletal disorders in Switzerland (unspecified route)